1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,200 | 14,300 | 13:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Pharming Group N.V.: Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day | 612 | GlobeNewswire (Europe) | Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces... ► Artikel lesen | |
| Mo | With FDA rejections, Aquestive's shares go up, while Pharming's go down | 13 | FiercePharma | ||
| Mo | FDA Strikes Off European Biotech Pharming's Immune Deficiency Drug For Expanded Use In Pediatric Patients | 13 | Benzinga.com | ||
| Mo | FDA knocks back Pharming's bid for wider Joenja use | 5 | pharmaphorum | ||
| Mo | Pharming Group N.V. - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| Mo | Pharming Group Receives FDA Complete Response Letter For Joenja Pediatric SNDA | 12 | RTTNews | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| So | Pharming Group N.V.: Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja (leniolisib) in children aged 4 to 11 years with APDS | 506 | GlobeNewswire (Europe) | Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL)... ► Artikel lesen | |
| 21.01. | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | 334 | EQS Group (EN) | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
21.01.2026 / 16:13 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 08.01. | Pharming Group N.V. - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 08.01. | Pharming Group Sees Higher-than-Expected Revenues In Fiscal 2025 | 6 | RTTNews | ||
| 08.01. | Pharming Group N.V.: Pharming Group reports preliminary 2025 revenues and announces Investor Day | 537 | GlobeNewswire (Europe) | Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full... ► Artikel lesen | |
| 08.12.25 | Pharming Group N.V.: Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit | 350 | GlobeNewswire (Europe) | Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit... ► Artikel lesen | |
| 06.11.25 | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 06.11.25 | Pharming GAAP EPS of $0.01 beats by $0.01, revenue of $97.3M beats by $4.46M | 6 | Seeking Alpha | ||
| 06.11.25 | Pharming Group N.V.: Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow | 542 | GlobeNewswire (Europe) | Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024... ► Artikel lesen | |
| 30.10.25 | Pharming Group N.V.: Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London | 464 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare... ► Artikel lesen | |
| 23.10.25 | Pharming Group N.V.: Pharming Group to report third quarter 2025 financial results and provide business update on November 6 | 414 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the... ► Artikel lesen | |
| 22.10.25 | Pharming Group N.V. - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 20.10.25 | Pharming Group N.V.: Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio | 5 | GlobeNewswire (USA) | ||
| 06.10.25 | Pharming Group N.V.: Pharming Group provides update on previously announced G&A expense reduction plan | 350 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 10,320 | -0,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | +2,10 % | PacBio Completes Sale of Short-Read Sequencing Assets | MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of... ► Artikel lesen | |
| ATAIBECKLEY | 3,770 | +10,56 % | Psychodelika-Aktien: Sind Bioxyne, Compass Pathways und Atai "the next big thing"? | ||
| BIOMERIEUX | 96,35 | +1,31 % | BIOMERIEUX: bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies | ||
| LIR LIFE SCIENCES | 0,844 | -2,09 % | LIR Life Sciences beginnt mit der zweiten Projektphase des Peptid-Entwicklungsprogramms in Zusammenarbeit mit Neuland Laboratories | Vancouver, Kanada - 5. Februar 2026 / IRW-Press / LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (FWB: N790, WKN: A41QA9) ("LIR"
oder das "Unternehmen") freut sich bekannt zu geben, dass... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 1,070 | +28,92 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| ASSERTIO | 12,740 | +9,64 % | Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split | LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation... ► Artikel lesen | |
| GENUS | 34,800 | -1,69 % | Genus completes formation of Chinese porcine joint venture | ||
| ANAPTYSBIO | 42,200 | 0,00 % | AnaptysBio, Inc.: Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary | Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology... ► Artikel lesen | |
| ABIONYX PHARMA | 3,640 | -2,02 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,825 | 0,00 % | XTL Biopharmaceuticals Ltd.: XTL Update on Recent Developments | RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced that it is working diligently to close the acquisition... ► Artikel lesen | |
| AKESO | 10,700 | -1,83 % | AKESO (09926): VOLUNTARY ANNOUNCEMENT - AKESO GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS FOR EBRONUCIMAB INJECTION TO JUMPCAN PHARMACEUTICAL | ||
| MEIRAGTX | 6,150 | -2,38 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| MAAT PHARMA | 7,000 | -1,13 % | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,041 | -6,86 % | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,200 (-1,49 %) liegt der Kurs bei 13,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.